VJOncology is committed to improving our service to you

ASCO 2020 | PSMA-targeted alpha emitter 225Ac-J591 for mCRPC

VJOncology is committed to improving our service to you

Scott Tagawa

Scott Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York, NY, USA, discusses a Phase I dose-escalation study (NCT03276572) of the PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter